Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026

About this update from Helix Biopharma Corp.

VANCOUVER, BC - June 12, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today reported financial results and the filing of the Company's unaudited interim financial statements as of and for the three- and nine-month periods ended April 30, 2026 (the "Financial Statements"), the management's discussion and analysis ("MD&A"), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, "CEO" and "CFO") relating to the Financial Statements (collectively, the "Interim Filings"). All values are in Canadian dollars unless stated otherwise. "Since the beginning of the year, our focus has been on securing the capital necessary to support Helix's near-term operating and development objectives," said Thomas Mehrling, MD, PhD, Chief Executive Officer of the Company. "With the successful completion of our recent private placement, we have made substantial progress toward our objective of establishing approximately twelve months of operating runway. This financing strengthens our ability to execute against our strategic priorities, including ongoing preparations for a U.S. exchange listing as we work to expand access to capital, advance L-DOS47 toward the clinic, and create long-term shareholder value." Financial Highlights: - The Company incurred a net and total comprehensive loss from operations of $671,000 for the three months ended April 30, 2026, and a loss of $2,374,000 for the nine months ended April 30, 2026, versus a net loss of $1,544,000 and $4,255,000 for the three and nine months ended April 30, 2025, respectively. The decrease in net loss was primarily due to reduced research and development expenses and the closing out of the Company's LDOS006 clinical study, partially offset by an increase in operating, general and administrative expenses associated with accounting, tax, legal, and consulting fees. - The net and total comprehensive loss for the reporting period corresponds to a loss of $0.01 and $0.03 per common share for the three and nine months ended April 30, 2026, respectively, versus a loss ...

View stock analysis, news, and events for Helix Biopharma Corp.